These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 23712330

  • 21. Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma.
    Benzeid R, Gihbid A, Tawfiq N, Benchakroun N, Bendahhou K, Benider A, Guensi A, El Benna N, Filali Maltouf A, Attaleb M, Chaoui I, Khyatti M, El Mzibri M.
    Asian Pac J Cancer Prev; 2023 Jan 01; 24(1):93-99. PubMed ID: 36708557
    [Abstract] [Full Text] [Related]

  • 22. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
    Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M.
    BMC Med Genet; 2018 Jul 06; 19(1):112. PubMed ID: 29980176
    [Abstract] [Full Text] [Related]

  • 23. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1237-46. PubMed ID: 15709194
    [Abstract] [Full Text] [Related]

  • 24. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH, Hua D, Du X.
    Cancer Chemother Pharmacol; 2009 Oct 01; 64(5):1001-7. PubMed ID: 19247656
    [Abstract] [Full Text] [Related]

  • 25. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y, Wu Y, Li W, Kong Z, Zou X.
    Int J Clin Exp Pathol; 2015 Oct 01; 8(7):7905-12. PubMed ID: 26339355
    [Abstract] [Full Text] [Related]

  • 26. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
    Shen C, Chen L, Fu J, Lin H.
    J Cancer Res Ther; 2016 Oct 01; 12(Supplement):72-75. PubMed ID: 27721259
    [Abstract] [Full Text] [Related]

  • 27. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug 01; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 28. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
    Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC.
    Clin Cancer Res; 2005 Feb 15; 11(4):1534-8. PubMed ID: 15746057
    [Abstract] [Full Text] [Related]

  • 29. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
    Sun JM, Ahn MJ, Park MJ, Lee HY, Ahn JS, Lee S, Kang G, Han J, Son YI, Baek CH, Ahn YC, Park K.
    Int J Radiat Oncol Biol Phys; 2011 Jul 01; 80(3):655-60. PubMed ID: 21621119
    [Abstract] [Full Text] [Related]

  • 30. Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
    Pacetti P, Giovannetti E, Mambrini A, Nannizzi S, Orlandi M, Tartarini R, Del Freo A, Del Tacca M, Danesi R, Cantore M.
    Anticancer Res; 2009 May 01; 29(5):1835-40. PubMed ID: 19443413
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
    Wang D, Zhou J, Zheng J, Zhang J, Chen Y, Li W, Wang R.
    Cancer Biomark; 2018 May 01; 21(4):875-881. PubMed ID: 29439312
    [Abstract] [Full Text] [Related]

  • 33. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V, Sirera R, Bremnes RM, Blasco A, Jantus-Lewintre E, Tarón M, Berrocal A, Blasco S, Caballero C, Del Pozo N, Rosell R, Camps C.
    Clin Lung Cancer; 2011 Jul 01; 12(4):224-30. PubMed ID: 21726821
    [Abstract] [Full Text] [Related]

  • 34. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
    Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.
    Cancer Chemother Pharmacol; 2011 Oct 01; 68(4):935-44. PubMed ID: 21298384
    [Abstract] [Full Text] [Related]

  • 35. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, Zhang B, Au WW, Xu X.
    Int J Hyg Environ Health; 2010 Mar 01; 213(2):140-5. PubMed ID: 20189873
    [Abstract] [Full Text] [Related]

  • 36. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, Gallardo E, Lopez R, Carracedo A, Barros F.
    Pharmacogenomics; 2011 Mar 01; 12(3):433-42. PubMed ID: 21449681
    [Abstract] [Full Text] [Related]

  • 37. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
    Dai Q, Luo H, Li XP, Huang J, Zhou TJ, Yang ZH.
    Mutagenesis; 2015 May 01; 30(3):441-9. PubMed ID: 25690281
    [Abstract] [Full Text] [Related]

  • 38. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
    Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, Deng Q, Smith S, Yu H.
    Lung Cancer; 2007 May 01; 56(2):281-8. PubMed ID: 17222938
    [Abstract] [Full Text] [Related]

  • 39. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 01; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 40. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
    Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G.
    Pharmacogenet Genomics; 2009 Aug 01; 19(8):613-25. PubMed ID: 19620936
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.